Benzamides and nicotinamides as Syk modulators

Patent metadata

Field	Value
Publication number	US-9359375-B2
Application number	US-201414458163-A
Country	US
Kind code	B2
Filing date	Aug 12, 2014
Priority date	Nov 1, 2010
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

First claim

What is claimed is:

1. A method for treating a condition or disease selected from the group consisting of a hematological malignancy, rheumatoid arthritis, systemic lupus erythematosus, asthma, and Type 1 diabetes in a subject comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound having the formula (I):

or a tautomer thereof or a pharmaceutically acceptable salt or hydrate thereof, wherein:
Q 1 is CX 1 ; Q 2 is CX 1 or N;
each X 1 is independently selected from the group consisting of: hydrogen, C 1-8 alkyl, halogen, cyano, and aminocarbonyl;
X 2 is H or halogen;
D 1 is selected from the group consisting of:
(a) aryl;
(b) heteroaryl; and
(c) heterocyclyl;
each R 1 is independently selected from the group consisting of C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkoxy, C 1-8 alkylthio, aminocarbonyl, C 1-8 alkoxycarbonylC 1-8 alkylene, C 1-8 alkoxycarbonylC 1-8 alkoxy, C 1-8 alkoxycarbonylamino, oxo, halo, cyano, haloC 1-8 alkyl, haloC 1-8 alkoxy, aminosulfonyl, heteroarylsulfinyl; amino, hydroxyl, C 1-8 arylalkylene, phenyl, aminoC 1-8 alkyl, aminoC 3-8 cycloalkyl, heterocyclyl, heteroaryl, heterocyclylC 1-8 alkylene and hydroxyC 1-8 alkylene;
D 2 is selected from the group consisting of:

R 3a is selected from the group consisting of: H, C 1-8 alkyl, C 1-8 alkenyl, hydroxyl, oxo, amino, thio, halo, carboxy, aminocarbonyl, C 1-8 alkoxy, haloC 1-8 alkoxy, C 1-8 alkylamino, diC 1-8 alkylamino, cyano, C 1-8 alkylthio, C 1-8 alkylsulfonyl, aminocarbonyl, C 1-8 alkoxycarbonylamino, C 1-8 alkylC 3-8 cycloalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyloxy, C 3-8 cycloalkylamino, C 3-8 cycloalkylthio, heteroaryl, heteroarylalkoxy, aryl, arylalkoxy, heterocyclyl and heterocyclyloxy; wherein the aryl is optionally substituted by hydroxyl, C 1-8 alkyl, C 1-8 alkoxy, halo, haloC 1-8 alkyl, C 1-8 alkylsulfonyl or heteroaryl;
R 3b is selected from the group consisting of: H and C 1-8 alkyl; or may be combined with R 3a to form a 3 to 8 membered carbocyclic or heterocyclic ring;
R 3c is selected from the group consisting of: H, C 1-8 alkyl and C 3-8 cycloalkyl; or taken together with R 3d and the atoms to which they are attached to form a heterocyclyl ring;
R 3d is selected from the group consisting of: H, C 1-8 alkyl and C 3-8 cycloalkyl;
L 2 is selected from the group consisting of a bond and C 1-8 alkylene;

R 4a is independently selected from the group consisting of: C 1-8 alkyl, hydroxyC 1-8 alkyl, C 1-8 haloalkyl, amino, C 1-8 alkylamino, C 1-8 alkoxycarbonylaminoC 1-8 alkylene, C 3-8 cycloalkyl, heteroaryl, C 1-8 alkylC 3-8 cycloalkyl, C 1-8 alkylthioC 1-8 alkyl, C 1-8 alkylsulfonylC 1-8 alkylene, aminocarbonyl, C 1-8 alkoxyC 1-8 alkyl, C 1-8 alkoxyC 1-8 alkoxy, haloC 1-8 alkyl, aryl and heterocyclyl; wherein the aryl is optionally substituted by hydroxyl, C 1-8 alkoxy, halo or haloC 1-8 alkyl; or taken together with R 4b and the atoms to which they are attached to form a C 3-8 cycloalkyl or hetercycloalkyl ring;
R 4b is selected from the group consisting of C 1-8 alkyl, C 1-8 alkylamino, amino, aminoC 1-8 alkyl, carboxy, C 1-8 alkylaminoC 1-8 alkyl, C 1-8 alkoxyC 1-8 alkyl, hydroxyC 1-8 alkyl; carboxyC 1-8 alkyl, C 3-8 cycloalkylC 1-8 alkyl, aryloxyC 1-8 alkyl, arylC 1-8 alkyl, heteroarylC 1-8 alkyl, and hydroxyC 1-8 alkoxy; or may be combined with R 4a or R 4c and the atoms to which they are attached to form a C 3-8 cycloalkyl or heterocyclyl ring;
R 4c is H or alkyl or may be combined with R 4b and the atoms to which they are attached to form a C 3-8 cycloalkyl or heterocyclyl ring;
(d) C 3-8 cycloalkyl; optionally substituted with from 1 to 3 substituents, R 6a , independently selected from the group consisting of C 1-8 alkyl, C 1-8 alkoxyC 1-8 alkyl, aminocarbonyl-, hydroxy, oxo, halogen, C 1-8 alkoxy and C 1-8 alkylsulfonyl;
(e) heterocycloalkyl; optionally substituted with from 1 to 3 substituents, R 6a , independently selected from the group consisting of C 1-8 alkyl, C 1-8 alkoxyC 1-8 alkyl, aminocarbonyl-, hydroxy, oxo, halogen, C 1-8 alkoxy and C 1-8 alkylsulfonyl; and
(f) arylalkylene; optionally substituted with from 1 to 3 substituents, R 6a , independently selected from the group consisting of C 1-8 alkyl, C 1-8 alkoxyC 1-8 alkyl, aminocarbonyl-, hydroxy, oxo, halogen, C 1-8 alkoxy and C 1-8 alkylsulfonyl;
each R 2 is independently selected from the group consisting of H and C 1-8 alkyl;
the subscript n is 0, 1, 2, 3 or 4; and the wavy line indicates the point of attachment to the rest of the molecule.

2. The method of claim 1 , wherein said condition or disease is selected from the group consisting of asthma, systemic lupus erythematosus, and Type I diabetes.

3. The method of claim 1 , wherein said disease is rheumatoid arthritis.

4. The method of claim 1 , wherein said hematological malignancy is selected from the group consisting of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma.

5. The method of claim 1 , wherein the compound has the formula (Ia):

or a tautomer thereof or a pharmaceutically acceptable salt or hydrate thereof.

6. The method of claim 1 , wherein the compound has the formula (Ib):

or a tautomer thereof or a pharmaceutically acceptable salt or hydrate thereof.

7. The method of claim 1 , wherein the compound has the formula (Ic):

wherein each Y 1 and Y 2 is each independently selected from the group consisting of: O, CR 2 , NH, NCOCH 3 and S.

8. The method of claim 1 , wherein the compound has the formula (Id):

Wherein each R 9a and R 8b is independently H or F.

9. The method of claim 1 , wherein the compound has the formula (Ie):

wherein each Y 1 and Y 2 is each independently selected from the group consisting of: O, CR 2 , NH, NCOCH 3 and S.

10. The method of claim 1 , wherein the compound has the formula (If):

11. The method of claim 1 , wherein the compound has the formula (Ig):

12. The method of claim 1 , wherein the compound has the formula (Ih):

13. The method of claim 1 , wherein the compound has the formulae (Ii):

14. The method of claim 1 , wherein a co

Assignees

• Portola Pharm Inc

Inventors

• Jia Zhaozhong J
• Song Yonghong
• Xu Qing
• Kane Brian
• Bauer Shawn M
• Pandey Anjali

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P7/06

  Antianaemics · CPC title